Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases.
BACKGROUND
Hemorrhagic cystitis (HC) is an important cause of morbidity in patients undergoing allogeneic stem-cell transplantation (SCT). Various causes have been identified, such as the use of high-dose cyclophosphamide or busulfan and the occurrence of acute graft-versus-host disease or viral infections (cytomegalovirus, adenovirus, polyomavirus).


METHODS
The clinical course of four patients treated with factor XIII (FXIII) concentrate for severe HC after allogeneic SCT is described.


RESULTS
Four patients were treated with one or two infusions of 50 IU/kg of FXIII concentrate. Only one patient showed a plasmatic FXIII decrease before treatment. Three of the four patients responded to this treatment, and HC completely resolved in two of them. No adverse event was observed.


CONCLUSIONS
The use of FXIII concentrate can improve the major symptoms of HC in patients with decreased or normal FXIII plasma level after allogeneic SCT.
Demesmay
Karine
K
Department of Pharmacy, Besançon University Hospital, Boulevard Fleming, 25030 Besançon Cedex, France.
Tissot
Edgar
E
Bulabois
Claude-Eric
CE
Bertrand
Marie-Anne
MA
Racadot
Evelyne
E
Woronoff-Lemsi
Marie-Christine
MC
Cahn
Jean-Yves
JY
Deconinck
Eric
E
D000328:Adult; D003556:Cystitis / Q000150:complications*; D005176:Factor XIII / Q000008:administration & dosage*; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous
D005176:Factor XIII